Computational Pathology – The Next Revolution in Cancer Diagnostics for Drug Development

Time: 9:00 am
day: Day One


  • Computational Pathology provides greater analytical precision and potentially greater clinical accuracy enabling identification of best patients populations for clinical response to oncology therapies
  • Quantitative Continuous Scoring (QCS) was developed to both quantify target expression in individual tumour cells and to quantify spatial heterogeneity of expression
  • We will discuss how we are leveraging Computational Pathology approaches in drug development and our vision for Computational Pathology in drug development